The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorCairo University

About this trial

To investigate the effectiveness of ultra-Sound guided Erector spinae block (ESB) with Betamethasone as an adjuvant to standard medical protocol in the management of truncal chronic post herpetic neuralgia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients age between 18 and 75.

Patients with American Society of Anesthesiologists (ASA) II and III status.

Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance )

Disqualifiers

Patients unable to comprehend the informed consent.

Patients on long term opioid regimens.

Patients with impairment in hepatic (Alanine aminotransferase (ALT) >50 U/L, and/or Aspartate aminotransferase (AST): >45 U/L) or renal functions( creatinine level ≥1.5 mg/dL)

Patients on anti-coagulation regimens.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Medical management regimen

    Other intervention

    Patients will receive the standard medical regimen alone.

  • Erector spinae plane (ESP) block

    Other intervention

    Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Med groupActive comparator 1 intervention
Group B: Erector spinae plane block groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pain degree

The degree of pain will be obtained and recorded on a numeric rating scale (NRS) with 0=no pain, and 10=Maximum pain intensity. Pain NRS score will be assessed at 2,4,6,8 weeks after the first clinic visit.

Time frame
8 weeks after the first clinic visit.

Secondary outcomes

1

Incidence of side effects

Incidence of side effects for medications regimen (excessive sleepiness, nausea, vomiting allergic reaction, diarrhea, blurred vision, disorientation).

Time frame
8 weeks after the first clinic visit.
2

Incidence of side effects

Incidence of side effects for ESP block (local hematoma, limb numbness or weakness, dizziness, pneumothorax, hypotension, infection, allergic reaction).

Time frame
8 weeks after the first clinic visit.
3

Tramadol consumption in both groups.

Total consumption of tramadol in both groups will be recorded

Time frame
8 weeks after the first clinic visit.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.